Purification and characterisation of tumour necrosis factor-alpha with cytotoxic activity against AK-5 cells. 1993

A Khar, and A M Ali, and P G Krishna, and A L Kumari
Centre for Cellular & Molecular Biology, Hyderabad, India.

Tumour necrosis factor (TNF) has been purified from the sera of animals in which the rat histiocytoma AK-5, was rejected spontaneously. Purified TNF-alpha is cytotoxic to AK-5 cells in vitro and the cytotoxic activity of TNF is completely neutralized by anti TNF antiserum. The circulating TNF levels are high by day 10 after the tumour transplantation. Animals which do not regress the tumour have very low levels of TNF in serum. Production of TNF by tumour regressing animals is part of the host immune response to the AK-5 tumour. Also, spleenomegaly in the animals which reject the AK-5 tumour is observed.

UI MeSH Term Description Entries
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D018219 Histiocytoma, Benign Fibrous A benign tumor composed, wholly or in part, of cells with the morphologic characteristics of HISTIOCYTES and with various fibroblastic components. Fibrous histiocytomas can occur anywhere in the body. When they occur in the skin, they are called dermatofibromas or sclerosing hemangiomas. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 5th ed, p1747) Dermatofibroma,Hemangioma, Sclerosing,Histiocytoma, Cutaneous,Histiocytoma, Fibrous,Angioma, Sclerosing,Benign Fibrous Histiocytoma,Angiomas, Sclerosing,Benign Fibrous Histiocytomas,Cutaneous Histiocytoma,Cutaneous Histiocytomas,Dermatofibromas,Fibrous Histiocytoma,Fibrous Histiocytoma, Benign,Fibrous Histiocytomas,Fibrous Histiocytomas, Benign,Hemangiomas, Sclerosing,Histiocytomas, Benign Fibrous,Histiocytomas, Cutaneous,Histiocytomas, Fibrous,Sclerosing Angioma,Sclerosing Angiomas,Sclerosing Hemangioma,Sclerosing Hemangiomas

Related Publications

A Khar, and A M Ali, and P G Krishna, and A L Kumari
January 1994, Therapeutic immunology,
A Khar, and A M Ali, and P G Krishna, and A L Kumari
June 2000, Cytokine,
A Khar, and A M Ali, and P G Krishna, and A L Kumari
January 1995, Acta oncologica (Stockholm, Sweden),
A Khar, and A M Ali, and P G Krishna, and A L Kumari
January 1991, Cell biology international reports,
A Khar, and A M Ali, and P G Krishna, and A L Kumari
January 1986, Nature,
A Khar, and A M Ali, and P G Krishna, and A L Kumari
August 1989, Journal of biological response modifiers,
A Khar, and A M Ali, and P G Krishna, and A L Kumari
March 1992, Molecular microbiology,
A Khar, and A M Ali, and P G Krishna, and A L Kumari
February 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy,
Copied contents to your clipboard!